Report #2851457

Received Jul 28, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 89 yrs
State: MA
Recovered: Unknown
Vaccinated: Apr 9, 2025
Onset: Apr 9, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	3x97j	SC

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Possible subcutaneous administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 89-year-old female patient who received Herpes zoster (Shingrix) (batch number 3x97j, expiry date 25-MAR-2027) for prophylaxis. On 09-APR-2025, the patient received Shingrix (subcutaneous). On 09-APR-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Possible subcutaneous administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date: 16-JUL-2025 The pharmacist called stating patient received dose of Shingrix from another pharmacy and it was possible they received it subcutaneously which led to intramuscular formulation administered by other route.